



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2541783 A1 2004/04/22

(21) **2 541 783**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2003/10/13
(87) Date publication PCT/PCT Publication Date: 2004/04/22
(85) Entrée phase nationale/National Entry: 2006/04/05
(86) N° demande PCT/PCT Application No.: GB 2003/004425
(87) N° publication PCT/PCT Publication No.: 2004/033002
(30) Priorités/Priorities: 2002/10/11 (GB0223578.6);
2002/10/11 (GB0223577.8)

(51) Cl.Int./Int.Cl. *A61M 1/36* (2006.01),
B01D 19/00 (2006.01)
(71) Demandeurs/Applicants:
MOOZYCKINE, ALEXEI, GB;
DINGLEY, JOHN, GB
(72) Inventeurs/Inventors:
MOOZYCKINE, ALEXEI, GB;
DINGLEY, JOHN, GB
(74) Agent: FASKEN MARTINEAU DUMOULIN LLP

(54) Titre : APPAREIL ET PROCEDE DE REDUCTION DE MICROBULLES DE GAZ
(54) Title: APPARATUS AND METHOD FOR REDUCTION OF GAS MICROBUBBLES

(57) **Abrégé/Abstract:**

Apparatus for removing microbubbles from blood incorporates a device through which the blood passes in a continuous linear flow. Devices which can be used are a magnetic device or a venturi device.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/033002 A3

(51) International Patent Classification⁷: **A61M 1/36**,
B01D 19/00

(21) International Application Number:
PCT/GB2003/004425

(22) International Filing Date: 13 October 2003 (13.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0223577.8 11 October 2002 (11.10.2002) GB
0223578.6 11 October 2002 (11.10.2002) GB

(71) Applicants and

(72) Inventors: **MOOZYCKINE, Alexei** [UA/GB]; 82 Vivian Road, Sketty, Swansea, West Glamorgan SA2 0UL (GB). **DINGLEY, John** [GB/GB]; 103A Swansea Road, Liangyfelach, Swansea SA5 7HX (GB).

(74) Agent: **COHEN, Alan, Nicol**; 2 Grove Place, Tatsfield, Nr Westerham, Kent TN16 2BB (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
5 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: APPARATUS AND METHOD FOR REDUCTION OF GAS MICROBUBBLES

(57) Abstract: Apparatus for removing microbubbles from blood incorporates a device through which the blood passes in a continuous linear flow. Devices which can be used are a magnetic device or a venturi device.



WO 2004/033002 A3

- 1 -

Apparatus and Method for Reduction of Gas Microbubbles.

The present invention relates to a method and a device for reducing gas microbubbles in liquids, particularly it relates to a method and device for the reduction of gas microbubbles formed in the bloodstream during the use of a cardiopulmonary bypass circuit.

The device is designed to be used with any standard cardiopulmonary bypass circuit and is aimed at reducing the amount of microbubbles in blood formed at any stage of the blood circuit, and ideally could be installed in the position prior to the cannula entrance.

It is well documented that gas microbubbles produced during cardiopulmonary bypass are predominantly responsible for serious postoperative psycho-neurological dysfunction. (Refs. 1-10). At present, neuropsychologic impairment, to which intraoperative cerebral microemboli are a principal cause, is the most common complication of coronary bypass surgery, (Refs. 1,2,4-10).

In numerous clinical studies of this phenomenon, Doppler ultrasonography (Refs. 1, 3-5,7,9,11,12) was used to detect the number of microemboli in the cerebral arteries of patients. It was found that these emboli are air microbubbles that are not eliminated by the arterial line filter, and further attempts to reduce the amount of these microbubbles using various traps have been disclosed (Refs. 7, 11).

One of the latest developments (Ref. 7) includes a dynamic bubble trap, placed in the arterial line between the arterial filter and arterial cannula, where the bloodstream is forced to rotate and bubbles are driven by centripetal force to the centre of the axial blood flow, where they are collected and returned to the cardiectomy reservoir. This design (Ref. 7) allows for a significant reduction of microbubbles in the arterial line, and as a consequence, a decrease of high-intensity transient signals in the brain of

- 2 -

patients was observed.

We have now devised a method and devices which can be used for the reduction of microbubbles in blood. The devices can be used with any standard cardiopulmonary
5 bypass circuit to reduce the amount of microbubbles in blood formed at any stage of the blood circuit prior to the cannula entrance.

According to the invention there is provided a method for reducing microbubbles in blood which method comprises passing the blood in a linear flow through a device in
10 which the microbubbles separate from the blood.

By linear is meant that the flow is substantially in one direction through the device.

The flow is preferably substantially laminar through the device.
15

This is different to the device of Ref. 7 where the bloodstream is forced to rotate and bubbles are driven by centripetal force to the centre of the axial blood flow and the flow through the device is not continuous.

20 One device which can be used in the present invention is a magnetic device and in one embodiment of the invention there is provided a method for reducing microbubbles in blood which method comprises passing the blood through a magnetic field formed by a magnet.

25 The invention also provides apparatus or a device for removing microbubbles from blood which comprises a device comprising (i) a conduit down which blood can be passed and (ii) a means for generating a magnetic field positioned so that blood flowing down the conduit passes through the magnetic field.

30 The device can be used in vivo in a situation where blood is passed from a body

- 3 -

(human or animal) through the device of the invention and then back to the body, for example, in conjunction with any of the existing blood circuits, e.g. the device can be used with any standard cardiopulmonary bypass circuit, in order to reduce the amount of gas microemboli in the bloodstream formed during cardiopulmonary bypass surgery, thus minimizing subsequent brain injury in cardiopulmonary surgery. In a typical circuit the blood is pumped through a blood reservoir, an oxygenator, a filter and/or bubble trap and back to the body. Usually there are regulators and controllers to control the rate of flow, etc. The invention is preferably located in the circuit after the excess of air/gas has been removed from the bloodstream using bubble traps or other filters.

It is thought that the invention works by solubilizing the remaining gas microbubbles in the blood and thus removing the risk of their interaction with and accumulation into the brain tissues/capillaries.

In use the magnetic treatment device comprises magnets (permanent or electro magnets) which can be located round a conduit such as a pipe, e.g. by clamping to the pipe or by having the magnets positioned around the outside of a pipe, so the pipe flows through a central magnetic field. The pipe can be any conventional pipework used in cardiopulmonary circuits and should be non-ferromagnetic. The magnet fields of the magnet or magnets can be made very strong if necessary by the use of so called "super magnets" made of strongly ferromagnetic alloys.

All other devices used to reduce microemboli trauma (filters, bubble traps, Venturi) are aimed at the reduction of the amount of gas microbubbles formed at any stage of cardiopulmonary bypass, apart from the very last one (arterial cannulation), determined only by the design, geometry and material of the aortic cannula, (Ref. 9) the magnetic device of the present invention is capable of reducing gas embolism even at this last stage by altering the surface tension of blood and thus preventing/reducing the formation of microbubbles at all stages of the heart bypass

- 4 -

blood circuitry.

5 Magnetic treatment devices (MTDs) have been used for treating water. In a simple case, the water passes through the applied magnetic field created by a permanent magnet or electromagnet (or a combination of these). Despite extensive controversy over the nature of water magnetic effect and even the existence of the effect itself (probably, resulting from the relatively subtle nature of the effect and a variety of conditions used by different researchers), at present there exists a convincing body of articles in various journals (Refs. 13 -63) documenting the studies of the long-term
10 electromagnetic radiation effect on fluids and its practical applications.

At present, MTDs commercially available for antiscala water treatment are relatively inexpensive and compact kits are available commercially from several manufacturers in the UK, US, Germany, Denmark and other countries.

15

In recent years the nature of magnetic water conditioning phenomenon has been studied using a variety of techniques and currently is thought to be attributed to water-air (water-gas) interface effects. Submicroscopic gas bubbles and clusters thereof in water of approximate diameter 1 - 10 nm, probably stabilized by ions, are
20 considered to be responsible for so-called "magnetic water memory" effect. This effect reveals itself in several recordable changes of water properties, including stabilization of the solution pH, changes/oscillations in conductivity and ζ (zeta) potential of colloids, reduction of metals corrosion and scale formation, inactivation of micro-organisms, enhancement of calcium efflux through biomembranes,
25 reduction of surface tension, fluorescence of hydrophobic and hydrophilic probes, etc. It has been shown that the magnetic treatment induces changes in the crystal structure of the precipitate formed in concentrated carbonate solutions, producing mainly aragonite instead of calcite, affecting the nucleation and crystal growth, (Ref. 39).

30 Surprisingly, the effect of "water magnetic memory" is long-lasting; changes in the

- 5 -

observed properties remain for several minutes to several hours after the water has been treated by radiofrequency (RF) radiation, microwaves, magnets or electromagnets, (Refs. 13,14,17,31,50). Usually, the magnetic treatment does not require very strong RF sources or powerful magnets, although the amplitude of the applied RF field influences the observed effects. It was observed that the “water magnetic memory” effect disappears after the liquid has been carefully outgassed. This prompted the researchers to suggest (Refs. 14,17, 31,59) that it is the perturbation of the liquid-gas interface resulting in formation of nanobubbles (Ref 13) (and not the presence of trace concentrations of Fe^{2+} ions, as was thought before (Ref. 15) that is responsible for the appearance of long-lasting effects which require hours to relax.

It has been found recently (Refs. 45-49) that magnetic water treatment also increases the chlorine retention by swimming pool water, suppressing free chlorine loss and thus inhibiting microbial growth.

Apparently, the main driving force behind the decrease in chlorine desorption can be found in reduced surface tension of the solution, after its exposure to the electromagnetic field, followed by changes in the solubility of the gas. We propose to apply the same effect to help solubilize the remaining oxygen (or any gas) microemboli in the blood, and thus reduce its effervescence in brain capillaries.

In general, the device containing a set of permanent or electro-magnets is clamped to/around the fluid pipe made of metal, plastic or any other material. The MTD does not require direct contact with the fluid, which is particularly important for artificial blood circulation systems, in order to minimize the allergic reactions of the body.

It is a feature of the present invention that the implementation of the magnetic devices of the present invention involves minimum expenditure (as MTDs can be easily incorporated into existing cardiopulmonary bypass equipment) and, once assembled,

- 6 -

do not require any special attention from the medical personnel.

Also, magnetic devices are extremely cost-effective and do not require sterilization as they do not work in direct contact with blood and do not have any moving parts, so
5 their lifetime is restricted only by the durability of the materials used for their clamps.

In another embodiment of the invention the device for gas in blood comprises a Venturi tube formed of a first and second truncated cone connected together at their narrower ends with an inlet for blood at the wider end of the first truncated cone and
10 an outlet for blood at the wider end of the second truncated cone.

The invention also provides a method for treating blood which comprises passing the blood through a Venturi device which comprises a Venturi tube formed of a first and second truncated cone connected together at their narrower ends with an inlet for
15 blood at the wider end of the first truncated cone and an outlet for blood at the wider end of the second truncated cone.

Preferably there is a connecting tube connecting the narrow ends of the first and second truncated cones.
20

The interior sides of the first and second truncated cones are preferably linear with a substantially constant angle of taper, although curved sides and varying angles of taper can be used, as in conventional Venturi devices. Preferably the interior surfaces of the truncated cones are smooth to facilitate laminar flow.

25

Venturi tubes are frequently used in hydraulic engineering for the measurement of flow rates (Refs. 13 – 22). A usual design of the Venturi tube (Refs. 13-18,21,22) includes two truncated cones (inlet and outlet) connected together by a short cylindrical pipe of a smaller diameter, called the throat and usually installed
30 horizontally.

- 7 -

When the blood is pumped through the Venturi device its velocity will increase as it passes down the first truncated cone which will reduce the pressure according to the modified Bernoulli's equation

$$h = \frac{P_1 - P_2}{\gamma} = \frac{v_2^2 - v_1^2}{2g} \quad (I)$$

where γ represents specific weight of the fluid, P_1 , P_2 and v_1 , v_2 represent pressure and velocity of the fluid in sections 1 and 2 corresponding to diameters D of the pipe and d of the throat, so that $v_2/v_1 = D/d$.

10

A ratio D/d around 4 or more is preferred as this produces a considerably low pressure at the throat, sufficient to cause liberation of the dissolved air/gas, (Refs. 14, 21,23,24).

15

The ratio D/d is limited for a given flow rate and temperature by the maximum allowed pressure drop in the throat; for too high ratios, the velocity of the fluid at the throat can be very high, and the resulting pressure drop too big, capable of producing a subatmospheric pressure (known as a Venturi vacuum, Ref. 21) and vaporization of the liquid at this point, (Ref. 14). This phenomenon, called *cavitation*, is a highly undesired event, (Ref. 25) as it can cause severe damage to the blood cells, therefore the D/d ratio should always be well below the cavitation threshold.

20

The converging section of the first truncated cone (upstream from the throat) preferably has a gradient (inclination to the longitudinal axis or half angle) 10-30 degrees, the diverging section (downstream from the throat) preferably has a gradient 2.5-14 degrees. A long cone/form modification of the Venturi tube, rather than a short cone one, can be more suitable for medical applications, as it has lower pressure loss (Ref. 17) and creates less turbulence to the fluid flow, thus minimizing the potential damage to the blood cells.

25

- 8 -

In the present invention preferably the device is positioned so that excess of the dissolved oxygen (or any other gas) is evolved from the blood prior to administration of the oxygenated blood to the patient.

5

Obviously, this procedure can only reduce the amount of oxygen dissolved in blood and does not affect in any way the amount of oxygen chemically bound to haemoglobin (neglecting very small changes in equilibrium constant), and thus does not change the uptake of aidful oxygen by the blood. Smooth laminar flow inside the
10 Venturi tubes does not cause haemolysis of erythrocytes and therefore does not reduce the uptake of oxygen even indirectly.

The device of the present invention can be used for the reduction of microbubbles in blood and can be used in conjunction with any of the bubble traps and filters, which
15 allows to improve the efficiency of the removal of gas microemboli from the bloodstream during cardiopulmonary bypass and to reduce subsequent brain injury.

In use a gradual pressure growth in the second, diverging, truncated cone cannot quickly dissolve back the bubbles that were formed and released in the throat of the
20 Venturi tube, (Ref. 23) so they are carried with the blood flow into a separating device or a blood filter installed downstream. The diameter of the outlet of the second truncated cone is preferably similar or larger than that of the inlet of the first truncated cone, in order to sustain a relatively slow fluid flow and to help the evolved gas to separate.

25

Optionally there can be a separating chamber positioned close to (or combined with) the outlet of the second truncated cone with an incorporated mesh (or several meshes) installed at an angle, β less than 90° to the direction of the flow. When the chamber is positioned horizontally, the bubbles, comparable or larger than the mesh size, travel
30 slowly along the mesh and up to the top part of the chamber. From there, a small

- 9 -

portion of blood, saturated with bubbles, is redirected back to the inlet of the blood pump *via* a bypass. The flow rate in the bypass can be regulated by a valve or clamp in order to obtain a desirable ratio of volumetric rates in the bypass and the main line (e.g. around 1/10).

5

The blood flow, instead of passing through the reclined mesh, can be directed into a short spiral tube or other device where the fluid is forced to rotate in order to allow the centripetal force to separate the bubbles. Alternatively, in the cardiopulmonary circuit installation, the device of the present invention can be immediately followed
10 by the dynamic bubble trap (Ref. 7) or any other conventional blood filter; in this case no special separation chamber need be incorporated into the device's design.

The design of the separating chamber is not relevant to the present invention as a separating chamber is needed only to separate the bubbles that have been evolved in
15 the Venturi tubes.

The advantages of using the Venturi tube (Refs. 13,17) over other devices include its ability to sustain relatively high flow rates, very small unrecovered pressure loss, h_L , normally less than 12 - 15 % of differential pressure, h , and, above all, the fluid flow
20 through the Venturi tube is smooth, without creating a turbulence. This latter point is very important, as blood cell damage and particularly haemolysis of red blood cells represents one of the most serious negative effects during cardiac surgery, (Ref. 9) and is thought to be caused by mechanical damage induced by the compulsory circulation, oxygenation, etc.

25

The Venturi tube can be installed vertically as the downward flow might be more effective than the conventional horizontal mode, as formed gas bubbles spend more time in the low pressure (throat) region due to their buoyancy (Ref. 26) and have more time to grow to a size large enough to be readily separated. Also, vertical
30 positioning of the Venturi tube reduces the area used, making the equipment more

- 10 -

compact and better adjusted to clinical conditions.

In the specification vertically and horizontally with regard to the Venturi device means that the axis of the first and second truncated cones are vertical or horizontal
5 respectively and so the axis of the throat is vertical or horizontal.

It is a feature of the present invention that the Venturi tube device is relatively inexpensive and can be made/assembled from any suitable materials that are adequate for handling blood, e.g. titanium or surgical stainless steel with or without coating,
10 polymers, composites, etc.

The Venturi tube device can be used to reduce the amount of gas microemboli formed at any stage of cardiopulmonary bypass apart from the last one (arterial cannulation), which is determined only by the design, geometry and material of the aortic cannula.
15 (Ref 9). The implementation of the Venturi device involves minimum expenditure as it can be easily incorporated into existing cardiopulmonary bypass equipment and does not require any special attention from the medical personnel. Also, the device is very simple to produce, cost-effective and reliable as it does not have any moving parts.

20

The invention is illustrated in the accompanying drawings in which:-

Fig. 1 shows schematically a circuit for treating blood using a magnetic device;
Fig. 2 shows a schematic view of the circuit incorporating a Venturi device and
25 Fig. 3 is a sectional view through the Venturi device of fig. 2.

Referring to fig. 1 a cardiopulmonary circuit comprises a blood pump (2), a blood reservoir (3), oxygenator (4), filter (5) a magnetic treatment device (6) for use with patient shown at (1). The magnetic treatment device consisted of a non-ferromagnetic
30 tube to the outside of which are clamped permanent magnets so that blood flowing

- 11 -

through the tube passes through the magnetic field.

In use blood from patient (1) is pumped around the circuit as shown by the arrows as in conventional cardiopulmonary circuits. When the blood passes through the device
5 (6) before being returned to the body the magnetic field of the device removes any microbubbles in the blood.

Referring to fig. 2 a cardiopulmonary circuit is shown in which there is a patient (11) from whom blood is pumped by pump (13) through reservoir (12), oxygenator (14),
10 Venturi device (15), filter (16) back to patient (11); there is regulating valve etc. at (17).

Referring to fig. 3, the Venturi device comprises a first truncated cone (9) which has an inlet (8) of diameter 'D', the outlet of the cone (9) is connected to tube (10) of
15 diameter 'd'. The outlet of tube (10) connects to the inlet of truncated cone (21). There is outlet (22) of truncated cone (21) which has a diameter 'D₁'.

In use, after the blood pump and optionally a small blood settling reservoir (not shown) the blood enters the inlet (8) of diameter 'D' and passes down first truncated
20 cone Venturi tube (9) through its narrow part (throat) (10) of diameter 'd', where the velocity of blood significantly increases and, according to the Bernoulli's formulae (I), the pressure drops sharply, the blood then flows down the second truncated cone (21) and out through outlet (22) of diameter D₁. This pressure drop allows some microbubbles that were previously dissolved in the blood to grow rapidly, effervesce
25 and to be eliminated from the bloodstream. The line *HGL* refers to Hydraulic Grade Line, (Refs. 13, 14) otherwise known as hydraulic gradient (Ref. 22) and reflects static pressure in the system; P_1/γ refers to ... , h is the differential pressure, and h_L is the unrecovered pressure loss.

References

1. R.L. Taylor, M.A. Borger, R.D. Weisel, L. Fedorko, C.M. Feindel, *Ann. Thorac. Surg.*, 1999, **68**, 89-93.
5
2. M.A. Borger, C.M. Peniston, R.D. Weisel, M. Vasiliou, R.E.A. Green, C.M. Feindel, *J Thorac. Cardio. Sur.*, 2001, **121**, 743-749.
3. S.M.F. Malheiros, A.R. Massaro, A.A. Gabbai, C.J.N. Pessa, L.R. Gerola, J.N.R. Branco, E.B. Lira, D.MJ. Christofalo, D. Federico, A.C. Carvalho, E. Buffalo,
10 *Arq. Neuro-Psiquiat.*, 2001, **59**, 1-5.
4. F. Schneider, J.F. Onnasch, V. Falk, T. Walther, R. Autschbach, F.W. Mohr, *Ann. Thorac. Surg.*, 2000, **70**, 1094-1097.
5. M.A. Borger, R.L. Taylor, R.D. Weisel, G. Kulkarni, M. Benarolia, V. Rao, G. Cohen, L. Fedorko, C.M. Feindel, *J. Thorac. Cardio. Sur.*, 1999, **118**, 740-745.
- 15 6. M.A. Borger, J. Ivanov, R.D. Weisel, V. Rao, C.M. Peniston, *Eur. J Cardio-Thorac.*, 2001, **19**, 627-632.
7. M. Schonburg, P. Urbanek, G. Erhardt, B. Kraus, U. Taborski, A. Muhling, S. Hem, M. Roth, H.J. Tiedtke, W.P. Klovekom, *Perfusion-UK*, 2001, **16**, 19-25.
8. A.B. Branger, D.M. Eckmann, *J Appli Physiol*, 1999, **87**, 1287-1295.
- 20 9. G.P. Gravlee, R.F. Davis, M. Kurusz, J.R. Utley, eds., *Cardiopulmonary Bypass : Principles and Practice*, Lippincott Williams & Wilkins, Philadelphia, 2000, pp. 49-97, and references therein.
10. H.P. Grocott, *J für Anästhesie und Intensivbehandlung*, 2002, **2**, 45-46.
11. X.M. Mueller, H.T. Tevæarai, D. Jegger, M. Austburger, M. Burki, L.K. von
25 Segesser, *Perfusion-UK*, 1999, **14**, 481-487.
12. S. Eitschberger, A. Henseler, B. Krasenbrink, B. Oedekoven, K. Mottaghy, *Asaio* 1,2001, **47**, 18-24.
13. M. Colic, D. Morse, *Phys. Rev. Lett.*, 1998, **80**, 2465-2468.
14. M. Colic, D. Morse, *Langmuir*, 1998, **14**, 783-787.

15. R.E. Herzog, Q. Shi, J.N. Patil, J.L. Katz, *Langmuir*, 1989, **5**, 861-867.
16. L.C. Lipus, J. Krope, L. Crepinsek, *J Colloid Interface Sci.*, 2001, **236**, 60-66.
17. M. Colic, D. Morse, *J. Colloid Interface Sci.*, 1998, **200**, 265-272.
18. K. Higashitani, H. Iseri, K. Okuhara, A. Kage, S. Hatade, *J Colloid Interface*
5 *Sci.*, 1995, **172**, 383-388.
19. L. Holysz, B. Chibowski, *J. Colloid Interface Sci.*, 1994, **165**, 243-251.
20. K. Higashitani, A. Kage, S. Kotamura, K. Imai, S. Hatade, *I. Colloid Interface*
Sd., 1993, **156**, 90-95.
21. K. Higashitani, K. Okuhara, S. Hatade, *J Colloid Interface Sci.*, 1992, **152**, 125-
10 131.
22. E. Chibowski, S. Gopalkrishnan, M.A. Bush, K.W. Bush, *J. Colloid Interface*
Sd., 1990, **139**, 43-54.
23. A. Goldsworthy, H. Whitney, E. Morris, *Water Res.*, 1999, **33**, 16 18-1626.
24. R.A. Barrett, S.A. Parsons, *Water Res.*, 1998, **32**, 609-612.
- 15** 25. Y. Wang, A.J. Babchin, L.T. Chernyi, R.S. Chow, R.P. Sawatzky, *Water Res.*,
1997, **31**, 346-350.
26. S.A. Parsons, B.-L. Wang, S.J. Judd, T. Stephenson, *Water Res.*, 1997, **31**, 339-
342.
27. J.S. Baker, S.J. Judd, *Water Res.*, 1996, **30**, 247-260.
- 20** 28. R. Gehr, Z.A. Zhai, J.A. Finch, S.R. Rao, *Water Res.*, 1995, **29**, 933-940.
29. J.M.D. Coey, S. Cass, *J Magnet. Magnet. Mater.*, 2000, **209**, 7 1-74.
30. J.J. Lin, J. Yotvat, *J Magnet. Magnet. Mater.*, 1990, **83**, 525-526.
31. M. Colic, D. Morse, *Colloids Surfaces A*, 1999, **154**, 167-174.
32. L. Yezek, R.L. Rowell, M. Larwa, E. Chibowski, *Colloids Surfaces A*, 1998,
25 **141**, 67-72.
33. K. Higashitani, J. Oshitani, N. Obmura, *Colloids Surfaces A*, 1996, **109**, 167-
173.
34. E. Chibowski, L. Holysz, *Colloids Surfaces A*, 1995, **101**, 99-101.
35. E. Chibowski, L. Holysz, W. Wójcik, *Colloids Surfaces A*, 1994, **92**, 79-85.

- 14 -

36. N. Su, Y.-H. Wu, C.-Y. Mar, *Cement Concrete Res.*, 2000, **30**, 599-605.
37. A. Chiba, W.-C. Wu, A. Terashita, *I. Mater. Sci.*, 1996, **31**, 3821-3825.
38. E. Chibowski, L. Holysz, M. Lubomska, *J Adhesion Sci. Technol.*, 1999, **13**, 1103-1117.
- 5 39. J.S. Baker, S.J. Judd, S.A. Parsons, *Desalination*, 1997, **110**, 151-165.
40. K.W. Busch, M.A. Busch, *Desalination*, 1997, **109**, 131-148.
41. N. Rocha, G. Gonzalez, L.C.doC. Marques, D.S. Vaitsman, *Petrol. Sci. Technol.*, 2000, **18**, 33-50.
42. Y. Zhao, L. Zhao, X. Wei, B. Han, H. Yan, *J. Therm. Anal.*, 1995, **45**, 13-16.
- 10 43. F.Y. Ishihara, S.M. Bradley, *J Imaging Technol.*, 1988, **14**, 157-160.
44. J.R. Newman, R.C. Watson, *Hydrobiologia*, 1999, **415**, 319-322.
45. J.E. Burgess, S.J. Judd, S.A. Parsons, *Process Safety Environ. Prot.*, 2000, **78**, 213-218.
46. K. Higashitani, J. Oshitani, *Process Safety Environ. Prot.* 1997, **75**, 115-119.
- 15 47. K.W. Busch, M.A. Busch, R.E. Darling, S. Maggard, S.W. Kubala, *Process Safety Environ. Prot.*, 1997, **75**, 105-114.
48. S.A. Parsons, S.J. Judd, T. Stephenson, S. Udol, B.-L. Wang, *Process Safety Environ. Prot.*, 1997, **75**, 98-104.
49. A.S.Ifll, J.S. Baker, S.J. Judd, *Process Safety Environ. Prot.*, 1996, **74**, 120-124.
- 20 50. M. Čolić, A. Chien, D. Morse, *Croatia Chem. Acta*, 1998, **71**, 905-916.
51. R.F. Benson, R. Lubosco, D.F. Martin, *J Environ. Sci. Health A*, 2000, **35**, 1527-1540.
52. S. Kobe, G. Dražić, P.J. McGuinness, J. Stražišar, *Acta Chim. Slov.*, 2001, **48**, 77-86.
- 25 53. L. Lipuš, J. Krope, L. Garbai, *Hung. J Ind. Chem.*, 1998, **26**, 109-112.
54. L. Lipuš, J. Krope, L. Garbai, *Hung. J. Ind Ghem.*, 1994, **22**, 239-242.
55. E.E. Fesenko, A.Y. Gluvstein, *FEBSLett.*, 1995, **367**, 53-55.
56. E.E. Fesenko, V.I. Geletyuk, V.N. Kazachenko, N.K. Chemeris, *FEBS Lett.*, 1995, **366**, 49-52.

- 15 -

57. V.I. Geletyuk, V.N. Kazachenko, N.K. Chemeris, E.E. Fesenko, *FEBSLett.*, 1995, **359**, 85-88.
58. C. Gabrielli, R. Jaouhari, G. Maurin, M. Keddam, *Water Res.*, 2001, **35**, 3249-3259.
- 5 59. M. Lubomska, B. Chibowski, *Langmuir*, 2001, **17**, 4181-4188.
60. J. Oshitani, R. Uehara, K. Higashitani, *J Colloid Interface Sci.*, 1999, **209**, 374-379.
61. J. Oshitani, D. Yamada, M. Miyahara, K. Higashitani, *J Colloid Interface Sci.*, 1999, **210**, 1-7.
- 10 62. M. Morimitsu, K. Shiomi, M. Matsunaga, *J Colloid Interface Sci.*, 2000, **229**, 641-643.
63. A. Khalil, R. Rosset, C. Gabrielli, M. Keddam, H. Perrot, *J Appl. Electrochem.*, 1999, **29**, 339-346.

- 16 -

Claims

1. A method for reducing microbubbles in blood which method comprises passing the blood in a linear flow through a device in which the microbubbles separate from the blood.
5
2. A method as claimed in claim 1 in which the flow is substantially laminar through the device.
- 10 3. Apparatus for removing microbubbles from blood which comprises (i) a conduit down which blood can be passed and (ii) a separating device through which the blood can flow in a continuous linear flow in which microbubbles separate from the blood.
- 15 4. Apparatus as claimed in claim 3 which comprises (i) a conduit down which blood can be passed and (ii) a means for generating a magnetic field positioned so that blood flowing down the conduit passes through the magnetic field.
- 20 5. Apparatus for treating blood as claimed in claim 3 which comprises (i) a pump (ii) an oxygenator (iii) a filter and (iv) a magnetic treatment device in which, in use, the pump pumps blood from a body through the oxygenator and filter and then through the magnetic treatment device and back to the body and in which the magnetic treatment device comprises a conduit down which the blood flows and at least one magnet located so that the blood flows through the magnetic field generated by the magnet.
25
6. Apparatus as claimed in claim 3 or 4 in which there is a blood reservoir, regulators and/or controllers through which the blood flows to control the rate of flow of the blood.
- 30 7. Apparatus as claimed in claim 3 or 4 in which the magnetic treatment device is

- 17 -

located after the excess of air/gas has been removed from the bloodstream using bubble traps or other filters.

8. Apparatus as claimed in any one of claims 3 to 7 in which the magnetic treatment
5 device comprises at least one permanent magnet or an electromagnet.

9. A method for reducing microbubbles in blood which method comprises passing the blood in a continuous linear flow through a magnetic field formed by a magnet.

10. A method for reducing microbubbles in blood as claimed in claim 9 which
10 comprises pumping blood from a patient and passing the blood through an oxygenator, a filter and a magnetic treatment device incorporating a conduit and a magnet so the blood flows down the conduit through the magnetic field generated by the magnet.

15

11. A device for treating blood as claimed in claim 3 which device comprises a Venturi tube formed of a first and second truncated cone connected together at their narrower ends with an inlet for blood at the wider end of the first truncated cone and an outlet for blood at the wider end of the second truncated cone.

20

12. Apparatus for treating blood as claimed in claim 3 which comprises (i) a pump (ii) an oxygenator, (iii) a filter and a Venturi device as claimed in claim 1 in which, in use, the pump pumps blood from a body through the oxygenator and filter and then through the said device and back to the body.

25

13. Apparatus as claimed in claim 12 in which the said device is positioned horizontally.

14. Apparatus as claimed in claim 12 in which the said device is positioned vertically.

30

- 18 -

15. Apparatus as claimed in any one of claims 11 to 14 in which there is a connecting tube connecting the narrow ends of the first and second truncated cones.

16. Apparatus as claimed in any one of claims 11 to 15 in which the interior sides of the first and second truncated cones are linear.

17. Apparatus as claimed in any one of claims 11 to 16 in which the ratio D/d where D is the diameter of the inlet of the first truncated cone and d is the diameter of the narrow end of the first truncated cone or the throat, is at least four.

10

18. Apparatus as claimed in any one of claims 11 to 17 in which the converging section of the first truncated cone (upstream from the throat) has a gradient of 10-30 degrees and the diverging section of the second truncated cone (downstream from the throat) has a gradient 2.5-14 degrees.

15

19. Apparatus as claimed in any one of claims 11 to 18 in which the length of the second truncated cone is longer than the length of the first truncated cone.

20. Apparatus as claimed in any one of claims 11 to 19 in which the diameter of the outlet of the second truncated cone is as at least as large as that of the inlet of the first truncated cone.

20

21. Apparatus as claimed in any one of claims 11 to 20 in which there is a separating means positioned close to, or combined with the outlet of the second truncated cone.

25

22. Apparatus as claimed in claim 21 in which the separating means comprises a separating chamber incorporating one or more meshes installed at an angle, β less than 90° , to the direction of the flow.

30 23. Apparatus as claimed in claim 21 in which the separating means comprises a

- 19 -

spiral tube or other device where the fluid is forced to rotate in order to allow the centripetal force to separate the bubbles.

24. Apparatus as claimed in claim 3 which comprises (i) a pump (ii) an oxygenator,
5 (iii) a filter and a Venturi device as claimed in any one of claims 11 to 23 in which, in use, the pump pumps blood from a body through the oxygenator and filter and then through the said device and back to the body and in which the Venturi device is positioned so that excess of the dissolved oxygen (or any other gas) is evolved from the blood prior to administration of the oxygenated blood to the patient.

10

25. A method for treating blood which method comprises passing the blood through a Venturi device as claimed in any one of claims 11 to 24.

15

26. A method for treating blood which comprises pumping the blood from a patient through a reservoir, an oxygenator, a filter, a Venturi device and back to the body and in which the Venturi device is as claimed in any one of the preceding claims 11 to 24.

1/3




Fig. 1

2/3




Fig. 2

3/3




Fig. 3